| Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals DD Waters, C Brotons, CW Chiang, J Ferrières, JA Foody, JW Jukema, ... Circulation 120 (1), 28-34, 2009 | 381 | 2009 |
| Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in … H Sillesen, P Amarenco, MG Hennerici, A Callahan, LB Goldstein, J Zivin, ... Stroke 39 (12), 3297-3302, 2008 | 373 | 2008 |
| Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine SH Preskorn, J Alderman, M Chung, W Harrison, M Messig, S Harris Journal of clinical psychopharmacology 14 (2), 90-98, 1994 | 256 | 1994 |
| Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes DD Waters, JE Ho, SM Boekholdt, DA DeMicco, JJP Kastelein, M Messig, ... Journal of the American College of Cardiology 61 (2), 148-152, 2013 | 251 | 2013 |
| Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor … P Rossignol, D Dobre, JJV McMurray, K Swedberg, H Krum, ... Circulation: Heart Failure 7 (1), 51-58, 2014 | 250 | 2014 |
| Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder EH Cook, KD Wagner, JS March, J Biederman, P Landau, R Wolkow, ... Journal of the American Academy of Child & Adolescent Psychiatry 40 (10 …, 2001 | 194 | 2001 |
| Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial LB Goldstein, P Amarenco, J Zivin, M Messig, I Altafullah, A Callahan, ... Stroke 40 (11), 3526-3531, 2009 | 169 | 2009 |
| Repositioning of the global epicentre of non-optimal cholesterol Nature 582 (7810), 73-77, 2020 | 130 | 2020 |
| Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial N Mauras, OH Pescovitz, V Allada, M Messig, MP Wajnrajch, B Lippe The Journal of Clinical Endocrinology & Metabolism 90 (7), 3946-3955, 2005 | 122* | 2005 |
| Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma volume: observations from the REVERSAL … SH Choi, A Chae, E Miller, M Messig, F Ntanios, AN DeMaria, SE Nissen, ... Journal of the American College of Cardiology 52 (1), 24-32, 2008 | 117 | 2008 |
| Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol … LB Goldstein, P Amarenco, M LaMonte, S Gilbert, M Messig, A Callahan, ... Stroke 39 (9), 2444-2448, 2008 | 108 | 2008 |
| Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial P Amarenco, LB Goldstein, M Messig, BJ O'Neill, A Callahan III, ... Stroke 40 (7), 2486-2492, 2009 | 89 | 2009 |
| Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial K Fagerström, H Gilljam, M Metcalfe, S Tonstad, M Messig Bmj 341, 2010 | 87 | 2010 |
| Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant C Parkinson, P Burman, M Messig, PJ Trainer The Journal of Clinical Endocrinology & Metabolism 92 (1), 190-195, 2007 | 85 | 2007 |
| Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder KD Wagner, EH Cook, H Chung, M Messig Journal of child and adolescent psychopharmacology 13 (2, Supplement 1), 53-60, 2003 | 76 | 2003 |
| Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials C Jimenez, P Burman, R Abs, DR Clemmons, WM Drake, KR Hutson, ... European Journal of Endocrinology 159 (5), 517-523, 2008 | 71 | 2008 |
| Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial P Raskin, C Huffman, C Toth, MJ Asmus, M Messig, RJ Sanchez, L Pauer The Clinical journal of pain 30 (5), 379-390, 2014 | 66 | 2014 |
| Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial P Amarenco, A Callahan III, VM Campese, LB Goldstein, MG Hennerici, ... Stroke 45 (10), 2974-2982, 2014 | 59 | 2014 |
| Low-and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2 RD Santos, DD Waters, L Tarasenko, M Messig, JW Jukema, J Ferrières, ... American heart journal 158 (5), 860-866, 2009 | 58 | 2009 |
| Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics: An Analysis From TNT … P Kohli, DD Waters, R Nemr, BJ Arsenault, M Messig, DA DeMicco, ... Journal of the American College of Cardiology 65 (4), 402-404, 2015 | 56 | 2015 |
